-
Innovation Ranking
NewInnovation Ranking – Axon Enterprise Inc
Axon Enterprise Inc (Axon) is a manufacturer of conducted electrical weapons. The company provides sensors hardware such as on body cameras, fleet in car video systems, and computer-aided dispatch software. It also provides evidence connected software network, software-as-a-service (SaaS) solutions and cloud-based records management system. It markets products under TASER and Axon brand names. Axon market its products and services to law enforcement, military, corrections, private security, healthcare security and individual clients. The company sells and distributes its products through...
-
Innovation Ranking
NewInnovation Ranking – Axonics Modulation Technologies Inc
Axonics Inc (Axonics) is a medical technology company that focuses on the design, development and commercialization of novel products for adults with bladder and bowel dysfunction. The company offers rechargeable and recharge-free sacral neuromodulation systems (SNM) including Axonics F15 and R20 systems for treating overactive bladder, fecal incontinence and urinary retention. It also offers Bulkamid, a urethral bulking agent for female stress urinary incontinence. The company has operations in Canada, Australia, the US and other regions in Europe. Axonics is...
-
Product Insights
NewLikelihood of Approval Analysis for Relapsing Multiple Sclerosis (RMS)
Overview How likely is it that the drugs in Relapsing Multiple Sclerosis (RMS) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Relapsing Multiple Sclerosis (RMS) Overview Multiple sclerosis (MS) is the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Iluzanebart in Neurodegenerative Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iluzanebart in Neurodegenerative Diseases report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iluzanebart in Neurodegenerative Diseases Drug Details: VGL-101 is under development for the...
-
Company Insights
Innovation and Patenting activity of Axonics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Axonics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Company Insights
Innovation and Patenting activity of Axon Enterprise Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Axon Enterprise Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewCardiac Ablation Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Cardiac Ablation Devices Pipeline Market Report Overview Cardiac ablation devices use radiofrequency energy to destroy cardiac tissues which propagate incorrect electrical signals to cause an abnormal heart rhythm. The cardiac ablation devices pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated...
-
Product Insights
Tauopathies – Drugs In Development, 2023
Global Markets Direct’s, ‘Tauopathies - Drugs In Development, 2023’, provides an overview of the Tauopathies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tauopathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Frontotemporal Dementia (FTD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Frontotemporal Dementia (FTD) - Drugs In Development, 2023’, provides an overview of the Frontotemporal Dementia (FTD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Frontotemporal Dementia (FTD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Sector Analysis
Neuromodulation Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Neuromodulation Devices Market Report Overview The neuromodulation devices market size was valued at $6.06 billion in 2023. Factors such as deep brain stimulation and spinal cord stimulation will drive the market growth at a CAGR of more than 6% from 2023 to 2033. Neuromodulation is one of the fastest-growing medical device markets. Within the last 10 years, the market has grown exponentially, with spinal cord stimulation being the largest market. Neuromodulation Devices Market Outlook 2023-2033 ($ Billion) Buy Full Report...